Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy

Launched by SHANGHAI MENTAL HEALTH CENTER · Aug 28, 2018

Keywords

ClinConnect Summary

Schizophrenia is one of the most serious mental illnesses worldwide that affects approximately 1% of the worldwide population and result in a heavy economic burden to affected family. Antipsychotics are the main stay of treatment of schizophrenia, however, there are still approximately 1/3 schizophrenia patients who does not responded to the antipsychotic agents, and these patients easily develop into treatment-refractory schizophrenia (TRS).

Clozapine is the only evidence based effective medication for treatment-refractory schizophrenia (TRS). In spite of its prominent efficacy, approxima...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
• • 18～60 years old
• • Clozapine resistance was defined as used at least two antipsychotics with different chemical structures with appropriate dosages for a sufficient duration, and recently have received stable dose of clozapine 400 mg or more per day for at least 6 months.
• • Signed an informed consent
• Exclusion Criteria:
• • Patients to be diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) for substance abused, development delayed
• • Suffering from serious physical disease and can not accept the treatment
• • Allergic to sodium valproate, amisulpride, propofol, succinylcholine or atropine
• • Participated in any clinical subject within 30 days
• • Pregnancy or lactation
• • Inability to sign informed consent because of capacity due due to severe mental illness, significant psychomotor agitation or slowness test completion